ES2384497T3 - Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo - Google Patents
Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo Download PDFInfo
- Publication number
- ES2384497T3 ES2384497T3 ES10151641T ES10151641T ES2384497T3 ES 2384497 T3 ES2384497 T3 ES 2384497T3 ES 10151641 T ES10151641 T ES 10151641T ES 10151641 T ES10151641 T ES 10151641T ES 2384497 T3 ES2384497 T3 ES 2384497T3
- Authority
- ES
- Spain
- Prior art keywords
- sars
- cov
- antibody
- mabs
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 title claims abstract description 78
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 49
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 39
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 86
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 19
- 108020003175 receptors Proteins 0.000 claims description 54
- 102000005962 receptors Human genes 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000000903 blocking effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002452 interceptive effect Effects 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 4
- 230000009918 complex formation Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 27
- 101710139375 Corneodesmosin Proteins 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 229940096437 Protein S Drugs 0.000 description 13
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 230000003389 potentiating effect Effects 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241001112090 Pseudovirus Species 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 238000012512 characterization method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 101710198474 Spike protein Proteins 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 108010066124 Protein S Proteins 0.000 description 5
- 102000029301 Protein S Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 244000309467 Human Coronavirus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282552 Chlorocebus aethiops Species 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000150562 Hantaan orthohantavirus Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000711466 Murine hepatitis virus Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 102000044437 S1 domains Human genes 0.000 description 2
- 108700036684 S1 domains Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- -1 of envelope E) Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229910020516 Co—V Inorganic materials 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108700002693 Viral Replicase Complex Proteins Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65104605P | 2005-02-08 | 2005-02-08 | |
US651046 | 2005-02-08 | ||
US14192505A | 2005-05-31 | 2005-05-31 | |
US141925 | 2005-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2384497T3 true ES2384497T3 (es) | 2012-07-05 |
Family
ID=36793717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10151641T Active ES2384497T3 (es) | 2005-02-08 | 2006-02-08 | Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1855719A4 (pt) |
JP (1) | JP2008529504A (pt) |
AT (1) | ATE556717T1 (pt) |
AU (1) | AU2006213775C1 (pt) |
BR (1) | BRPI0606148A2 (pt) |
CA (1) | CA2595780A1 (pt) |
ES (1) | ES2384497T3 (pt) |
MX (1) | MX2007009512A (pt) |
NZ (1) | NZ560328A (pt) |
WO (1) | WO2006086561A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015189422A1 (en) * | 2014-06-12 | 2015-12-17 | Universidade Do Porto - Reitoria | Vaccine for immunocompromised hosts |
CN113292650B (zh) * | 2020-02-24 | 2022-08-12 | 中国科学院微生物研究所 | 新型冠状病毒的人源单克隆抗体及其应用 |
CN113292649B (zh) * | 2020-02-24 | 2022-08-12 | 中国科学院微生物研究所 | 新型冠状病毒的人源单克隆抗体及其应用 |
CN111560074B (zh) * | 2020-03-20 | 2021-07-09 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 |
CN111983226A (zh) | 2020-03-25 | 2020-11-24 | 新加坡国立大学 | SARSr-CoV抗体的检测 |
WO2021202893A1 (en) * | 2020-04-03 | 2021-10-07 | Nonigenex, Inc. | Detecting adaptive immunity to coronavirus |
JP7174961B2 (ja) * | 2020-05-01 | 2022-11-18 | 花王株式会社 | 抗SARS-CoV-2抗体を用いた医薬品及び検査キット |
CN111995675B (zh) * | 2020-05-15 | 2021-03-23 | 潍坊医学院 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
WO2021238910A1 (en) * | 2020-05-25 | 2021-12-02 | Guo Bingshi | Anti-coronavirus spike protein antibodies and uses thereof |
CN112017782A (zh) * | 2020-06-01 | 2020-12-01 | 北京松果天目健康管理有限公司 | SARS-CoV-2易感性的检测方法及新冠病毒重症风险预测方法 |
JP2023531368A (ja) * | 2020-06-25 | 2023-07-24 | グリックニック インコーポレイテッド | Ace2-fc融合タンパク質および使用方法 |
CN113945714B (zh) * | 2020-07-16 | 2023-01-31 | 南京蓬勃生物科技有限公司 | 新型冠状病毒中和抗体类药物中和能力的检测方法 |
CN112010984B (zh) * | 2020-08-04 | 2021-10-12 | 广州千扬生物医药技术有限公司 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗 |
EP4206224A1 (en) | 2020-08-26 | 2023-07-05 | National University Corporation Kumamoto University | Human antibody or antigen-binding fragment thereof against coronavirus spike protein |
CN114181301B (zh) * | 2020-09-14 | 2023-04-28 | 复旦大学 | 针对SARS-CoV-2的无ADE效应的中和抗体 |
CN113156129B (zh) * | 2021-01-13 | 2022-04-05 | 广东菲鹏生物有限公司 | 中和抗体高敏检测方法及产品 |
CN115427441B (zh) * | 2021-01-27 | 2023-09-05 | 保诺生物科技(江苏)有限公司 | 针对sars-cov-2的抗体 |
CN115141271B (zh) * | 2021-01-31 | 2024-06-11 | 中南大学湘雅医院 | 新型冠状病毒单克隆抗体xy7及其应用 |
CN114859042B (zh) * | 2021-02-03 | 2023-11-03 | 广东菲鹏生物有限公司 | 一种鉴别结合突变型抗原的抗体的方法及试剂 |
EP4089112A1 (en) * | 2021-05-14 | 2022-11-16 | Ustav organicke chemie a biochemie AV CR, v.v.i. | Antibody binding to rbd of spike protein of sars-cov-2 and a method for quantifying protective antibodies against sars-cov-2 |
WO2023148641A1 (en) * | 2022-02-02 | 2023-08-10 | Translational Health Science And Technology Institute | Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof |
-
2006
- 2006-02-08 JP JP2007554351A patent/JP2008529504A/ja active Pending
- 2006-02-08 BR BRPI0606148-6A patent/BRPI0606148A2/pt not_active Application Discontinuation
- 2006-02-08 AU AU2006213775A patent/AU2006213775C1/en not_active Ceased
- 2006-02-08 WO PCT/US2006/004599 patent/WO2006086561A2/en active Application Filing
- 2006-02-08 EP EP06720569A patent/EP1855719A4/en not_active Withdrawn
- 2006-02-08 AT AT10151641T patent/ATE556717T1/de active
- 2006-02-08 ES ES10151641T patent/ES2384497T3/es active Active
- 2006-02-08 CA CA002595780A patent/CA2595780A1/en not_active Abandoned
- 2006-02-08 NZ NZ560328A patent/NZ560328A/en not_active IP Right Cessation
- 2006-02-08 MX MX2007009512A patent/MX2007009512A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2006213775B2 (en) | 2010-11-11 |
AU2006213775C1 (en) | 2011-11-03 |
CA2595780A1 (en) | 2006-08-17 |
JP2008529504A (ja) | 2008-08-07 |
AU2006213775A1 (en) | 2006-08-17 |
BRPI0606148A2 (pt) | 2009-06-02 |
MX2007009512A (es) | 2008-02-21 |
ATE556717T1 (de) | 2012-05-15 |
WO2006086561A3 (en) | 2009-04-23 |
NZ560328A (en) | 2010-05-28 |
EP1855719A4 (en) | 2009-11-04 |
WO2006086561A2 (en) | 2006-08-17 |
EP1855719A2 (en) | 2007-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2384497T3 (es) | Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo | |
US7629443B2 (en) | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus | |
He et al. | Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies | |
US11505597B2 (en) | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof | |
He et al. | Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design | |
Berry et al. | Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus | |
TW202200612A (zh) | SARS-Cov-2 (SARS2, COVID-19)抗體 | |
EP2193802B1 (en) | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus | |
CN101522208A (zh) | 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体 | |
Berry et al. | Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology | |
US20060240515A1 (en) | Soluble fragments of the SARS-CoV spike glycoprotein | |
CN107708726B (zh) | 抗体介导的切昆贡亚热病毒的中和 | |
He et al. | Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine | |
WO2007044695A2 (en) | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF | |
AU2005251738A1 (en) | SARS vaccines and methods to produce highly potent antibodies | |
He et al. | A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity | |
Bian et al. | Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody | |
Fouladirad et al. | Development of coronavirus treatments using neutralizing antibodies. Microorganisms. 2021; 9: 165 | |
Spike | Receptor-Binding Domain of Severe Acute | |
Spike | Antigenic and Immunogenic | |
Spike | Identification of an Antigenic Determinant |